2-38074404-C-T
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PM5PP3_ModeratePP5_Very_Strong
The ENST00000610745.5(CYP1B1):c.985G>A(p.Gly329Ser) variant causes a missense change. The variant allele was found at a frequency of 0.00000958 in 1,461,098 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G329D) has been classified as Pathogenic.
Frequency
Consequence
ENST00000610745.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP1B1 | NM_000104.4 | c.985G>A | p.Gly329Ser | missense_variant | 2/3 | ENST00000610745.5 | NP_000095.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CYP1B1 | ENST00000610745.5 | c.985G>A | p.Gly329Ser | missense_variant | 2/3 | 1 | NM_000104.4 | ENSP00000478561 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.0000121 AC: 3AN: 248888Hom.: 0 AF XY: 0.0000222 AC XY: 3AN XY: 135124
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1461098Hom.: 0 Cov.: 31 AF XY: 0.0000138 AC XY: 10AN XY: 726850
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Anterior segment dysgenesis 6 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 19, 2024 | - - |
Glaucoma 3A Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Nov 21, 2018 | The CYP1B1 c.985G>A (p.Gly329Ser) missense variant has been reported in one study and found in three individuals with primary congenital glaucoma including one each in a homozygous state, compound heterozygous state with a frameshift variant and heterozygous state (Kim et al. 2011). The variant was absent from 400 control chromosomes and is reported at a frequency of 0.000016 in the Total population of the Genome Aggregation Database. HEK293T cells expressing the p.Gly329Ser variant completely lacked retinol metabolizing activity (Banerjee et al. 2016). Based on the evidence, the p.Gly329Ser variant is classified as likely pathogenic for primary congenital glaucoma. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Primary congenital glaucoma Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 23, 2022 | Variant summary: CYP1B1 c.985G>A (p.Gly329Ser) results in a non-conservative amino acid change located in the conserved helixe I (aa316-349, Jeannot_2007) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 249004 control chromosomes (gnomAD and publication data). c.985G>A has been reported in the literature in individuals affected with Primary Congenital Glaucoma, including one homozygote (Kim_2011, Suh_2012). These data indicate that the variant may be associated with disease. Functional studies report experimental evidence evaluating an impact on protein function, where the variant protein was found to be enzymatically null for both estradiol and retinoic acid metabolism (Jeannot_2007, Banerjee_2016). In addition, other missense variants in the same residue (G329D and G329V) have been reported in the Human Gene Mutation Database in association with Primary Congenital Glaucoma (PMID: 17718864, 17893647), supporting the functional importance of this residue of the protein. Two ClinVar submitters have assessed the variant since 2014: one classified the variant as likely pathogenic, and one as of uncertain significance. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Congenital glaucoma Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 30, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 329 of the CYP1B1 protein (p.Gly329Ser). This variant is present in population databases (rs777678299, gnomAD 0.01%). This missense change has been observed in individuals with primary congenital glaucoma (PMID: 22942166). ClinVar contains an entry for this variant (Variation ID: 632362). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CYP1B1 protein function. Experimental studies have shown that this missense change affects CYP1B1 function (PMID: 17363580, 27243976). This variant disrupts the p.Gly329 amino acid residue in CYP1B1. Other variant(s) that disrupt this residue have been observed in individuals with CYP1B1-related conditions (PMID: 31024815), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at